| INTRODUC TI ON
Rheumatoid arthritis (RA) is an autoimmune disease, characterized by immune cell-mediated destruction of the joints. Hyper-reactive T and B lymphocytes are key cells in the destructive process by producing inflammatory cytokines and autoantibodies. 1 The protein tyrosine phosphatase non-receptor type 22 gene (PTPN22) encodes the lymphoid protein tyrosine phosphatase LYP, which is expressed exclusively in hematopoietic cells, including T and B cells. 2 LYP is a potent negative regulator of T and B lymphocyte activation by modulating T-cell receptor (TCR) and B-cell receptor (BCR) signaling.
3-6
A functional single nucleotide polymorphism (SNP) 1858C>T
(rs2476601) in the PTPN22 gene leads to the 620Arg>Trp substitution within the first pro-rich region in the C-terminus of LYP and has been consistently associated with RA susceptibility and anti-CCP antibodies seropositivity. [7] [8] [9] In the western Mexican population, this polymorphism has been found in low frequency (1858 T allele, 6%), however, it has been consistently associated with RA risk.
8,10
The mechanism of increased risk by the T allele remains unclear and controversial results have been exposed. Some authors have shown that this polymorphic allele (1858 T or 620Trp) is a gain-of-function variant, displaying a more potent inhibition on TCR and BCR signaling. 11, 12 On the other hand, it has also been shown that the same allele is a loss-of-function variant as it favors a hyperresponsive phenotype on several immune cells including T and B lymphocytes, and therefore, it is associated with the development of autoimmunity.
7,13-16
A study reported that the 1858 T risk allele interferes with the removal of developing autoreactive B cells and it is associated with an increase in CD40 expression on naïve B-cell surface. 17 CD40 is a costimulatory protein constitutively expressed on B cells, which promotes B-cell proliferation and differentiation, germinal center formation and antibody production by its interaction with its ligand, CD154.
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Furthermore, CD154 is expressed on the surface of activated T cells and is upregulated faster and to a higher degree in peripheral blood and synovial T cells from RA patients as compared to healthy controls, with the consequent increased production of pro-inflammatory cytokines such as IFN-γ. 19, 20 In addition, overexpression of CD154 on T cells correlates with higher RA activity. 21 To date, the functional role of the PTPN22 1858C>T polymorphism in autoimmune diseases is not entirely
clear and its precise impact on signaling pathways is highly context dependent. 6 Since the CD40/CD154 interaction promotes B-and T-cell activation and cytokine secretion, the aim of this study was to evaluate the relationship between the 1858 T risk allele with CD40 and CD154 expression and IFN-γ secretion in anti-CCP-positive RA patients.
| MATERIAL S AND ME THODS

| Study subjects and PTPN22 genotyping classification
In a previous study, 10 we determined the genotypes of PTPN22 1858C>T SNP in 315 RA patients and 315 control subjects from western Mexico using PCR-RFLP method. Participants were classified into two groups: carriers, for those who had at least one copy of the RA risk-conferring T allele (1858CT, 1858 TT), and not carriers, for those who were homozygous for the non-risk-conferring allele (1858CC). Taking these data into account, and considering the low frequency of this polymorphism, for this study, we selected a very specific cohort of patients, which consisted of the following: ten RA patients with an onset of maximum two years of clinical symptoms, positive for anti-CCP antibodies, and naïve to disease-modifying antirheumatic drugs (DMARDs). Ten CS with no family history of autoimmunity and no clinical signs of autoimmune or infectious disease, and negative for anti-CCP antibodies also were included.
This study was realized according to the Declaration of Helsinki.
The ethics and biosecurity committee of the "University Center for
Health Science, University of Guadalajara," approved this study and all subjects provided informed consent before their inclusion. A blood sample was obtained from every subject, from which peripheral blood mononuclear cells (PBMCs) and serum were obtained.
| Flow Cytometry for CD40 and CD154 molecules
Murine anti-human monoclonal antibodies (mAbs) anti-CD19-FITC, anti-CD4-FITC, anti-CD40-PE, anti-CD154-PE, and their respec- 
| IFN-γ quantification
Peripheral blood [5 mL] was collected and centrifuged at 300 g for 15 minutes to obtain the serum, which was stored at −70°C until processing by ELISA assays. Serum interferon gamma (IFN-γ) levels were analyzed using a commercially available ELISA kit (R&D Systems) conforming to the manufacturer's instructions. Detection limit for the assay was 0.8 pg/mL. 
| Statistics
| Carriers of the PTPN22 risk allele have increased counts of activated T cells and increased expression of mCD154
We Consequently, we analyzed the expression of mCD154 on CD4 + T cells from CS and RA but no significant differences were Figure 3B ). The same results were obtained when comparing CS ( Figure 3D ) and CS +RA patients, classified conforming to their genotypes.
Our results point out that the 1858 T PTPN22 allele is associated with a higher number of activated CD4+ T cells and an increased expression of mCD154.
| PTPN22 1858 T risk allele is associated with decreased IFN-γ serum levels
IFN-γ serum levels were measured in all subjects included. A borderline difference was detected when comparing CS levels versus RA levels regardless of their genotypes, being increased in RA patients Figure 4A ].
Intriguingly, the opposite was observed when the comparison was performed in CS ( Figure 4B ); there was a higher production of IFN-γ in CS carrying the risk allele, over those not carrying it 
| D ISCUSS I ON
The missense variant (1858C>T) of the protein tyrosine phosphatase non-receptor 22 (PTPN22) gene has one the strongest effects among RA-associated common variants, and it has been associated with over 20 different autoimmune diseases. 22 Surprisingly, the mechanisms underlying the association between PTPN22 and autoimmune diseases are still largely unknown.
The first study evaluating the association between RA and 1858C>T SNP reported an association only with rheumatoid factor positive RA, pointing out the possibility that PTPN22 1858 T allele affects autoantibody production. 7 These findings are consistent with our findings reported elsewhere. 8 In vitro assays have shown that the 1858 T risk allele leads to interference with the physical association between LYP and cSrc kinase (CSK), resulting in increased LYP activity. Supporting these findings, both TCR signaling and BCR signaling have been found to be reduced in the lymphocytes of risk allele carriers.
11,12,23
The interaction of the CD40 and CD154 molecules plays a significant role in T-and B-cell activation, as it increases cytokine production by T cells, as well as isotype change and antibody production by B lymphocytes. 24 Several authors report increased expression and soluble levels of these molecules in autoimmune diseases.
18
A previous study shows that the 1858 T allele of the PTPN22 gene is associated with increased CD40 expression on the naïve B-cell membrane of healthy subjects. 17 Therefore, in this study, we were interested in studying the effect of the 1858C>T PTPN22 polymorphism on the CD40 and CD154 expression in B and T cells membrane, correspondingly, as well as serum levels of IFN-γ in anti-CCP-positive RA patients.
Although in other autoimmune diseases such as systemic lupus erythematosus (SLE), several studies have shown differences in certain peripheral B-cell subsets compared to healthy subjects, 25 we did not find significant differences in the B cells percentage and CD40
MFI between CS and RA patients. In line with our results, it was accepted in consensus that there is a lack of differences on total pe- There is only one study suggesting that B-cell tolerance defects in autoimmunity can result from specific genetic variants, such as the 1858 T allele of the PTPN22 gene and precedes the onset of disease.
These authors demonstrated an increase in CD40 expression on naïve B cells of healthy subjects carrying the T allele. 17 In RA patients, we did not observe significant differences in the percentages or expression of CD40 on B cells conforming their genotype, and the same was observed when only CS as well as RA patients and CS combined were analyzed. Nevertheless, it is important to point out that the analyzed cells in that study were mature naïve B cells, whereas on our study total peripheral B cells were evaluated. Since the behavior of different cell subpopulations varies according to their maturation and activation status, this could explain the differences observed. Thus, our results suggest that the PTPN22 1858 T allele does not affect the expression of CD40 on total peripheral B cells. This is opposite to previous reports showing an increase in CD154 expression on the membrane of CD4+ T cells of RA patients. 31 These differences may be due to the disease activity score of our patients since it has been proposed that CD154 expression is directly associated with disease activity 21 which is evidenced, as we could not detect any differences because our group displayed a mean moderate activity. Altogether, these findings and ours provide novel mechanisms of action of the PTPN22 risk allele in RA.
Activated CD4+ T cells release high IFN-γ levels 35 ; this cytokine enhances chemokine expression for leukocyte recruitment by facilitating their transfer through the endothelial layer, increases antigen presentation, and promotes Th1 differentiation, 36 all of these functions are preponderant in the pathophysiology of RA. We observed a borderline significant increase in the IFN-γ serum levels of RA patients in relation to CS, which is in agreement with previous studies. 37, 38 Respecting to 1858C>T genotype, we observed that in the RA group, the presence of the risk allele favors a significant decrease in IFN-γ but intriguingly, in CS it is associated with an increase in IFN-γ levels. In this respect, a group of researchers documented that after in vitro antigen stimulation, CD4 + T cells from healthy donors carriers of 1858 T risk allele produced significantly higher amounts of IFN-γ and TNF-α than subjects carrying wild-type allele. 39 However, another study has shown in a case report that a type 1 diabetes patient with 1858 TT PTPN22 genotype has F I G U R E 4 PTPN22 1858 T risk allele association with serum levels of IFN-γ. Serum IFN-γ levels were analyzed using commercially available ELISA kit. A, Comparison of IFN-γ serum levels between RA patients classified as carriers (n = 5) and non-carriers (n = 5) of PTPN22 1858 T allele. B, Comparison of IFN-γ serum levels between CS classified as carriers (n = 3) and non-carriers (n = 7) of PTPN22 1858 T allele. C, Comparison of IFN-γ serum levels between RA patients and CS combined and classified as carriers (n = 8) and non-carriers (n = 12) of PTPN22 1858 T allele diminishing T-cell proliferation and reduced IFN-γ production. 40 This allows us to suggest that possibly the real effect of this polymorphism is that observed in control groups and that the discrepancy observed in RA patients could be because of other immunoregulatory cytokines, which may be elevated in response to the increase of IFN-γ caused by the T allele. It is also possible that the canonical signaling pathway behind IFN-γ induction is altered in RA. Our results suggest that when evaluating the effect of this polymorphism, not only the cell status should be considered, but the disease status as well, since several other factors and interactions may be involved that provoke different responses in patients as compared to healthy subjects.
The frequency of the PTPN22 1858 T allele varies considerably across the world; European populations have shown a higher frequency than other populations, 41 the T allele is virtually absent in
Han Chinese and Africans, whereas in African Americans the risk allele has been detected in intermediate frequencies (2.4%). 42 In the western Mexican population, the allelic frequency of this polymorphism is low (1858 T allele, 6%), which can be reflected in the low genotypic frequencies (CC = 96%, CT = 4%, and TT = 0%) observed at the general population. 8 One of the weaknesses of this study is that in our population,
we did not find individuals homozygous for the polymorphic variant; therefore, this makes it impossible to evaluate the effect of this polymorphism in a double dose. Also, we do not evaluate additional T-cell activation markers (eg, CD69, CD45RO) to verify the activation status of CD4+/CD154+ T cells.
In conclusion, our results suggest that the role of the 1858C>T 
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